Rituximab Suppliers & Bulk Manufacturers
Available Forms: IV Infusion; Subcutaneous
Available Strengths: IV infusion: 100 mg/10 mL, 500 mg/50 mL; SQ: 1400 mg/11 mL
Reference Brands: Rituxan®(US), MabThera®, Truxima®(EU);Ruxience®(US)
Category:
Oncology Cancer Care
Rituximab is a monoclonal antibody used to treat hematologic cancers and autoimmune diseases. It targets CD20 on B cells for cell destruction. Available as Rituxan® (US) and MabThera® (EU), Rituximab is offered in IV infusion and subcutaneous forms. Manufactured under GMP standards, it is a trusted option for oncology and autoimmune disease treatment, making it a reliable choice for pharmaceutical distributors across EU and US markets.
Rituximab is available in IV Infusion; Subcutaneous
and strengths such as IV infusion: 100 mg/10 mL, 500 mg/50 mL; SQ: 1400 mg/11 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Rituximab is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Rituximab can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Rituximab is a monoclonal antibody used for treating various hematologic cancers and autoimmune disorders. It targets CD20 on B cells, facilitating their destruction, and is effective for conditions such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. Available under Rituxan® in the US and MabThera® in the EU, Rituximab is supplied in IV infusion (100 mg/10 mL, 500 mg/50 mL) and subcutaneous (1400 mg/11 mL) formulations. Manufactured in GMP-compliant facilities, Rituximab is a trusted treatment option for oncology and autoimmune disease management, offering reliable solutions for pharma distributors across EU and US markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing